All Type of News
Eisai acquires domestic approval of ‘Lenvima,’ thyroid cancer treatment
Eisai Korea(President Hong-byung Ko) announced Eisai, a global pharmaceutical company, has acquired approval for its newly developed antibiotics, ‘Lenvima Cap(generic name: lenvatinib),’ as treatment of progressive di...
19 healthcare and biopharmaceutical businessmen participate the economic mission
19 businessmen in the healthcare and biopharmaceutical industries, such as President Jang-han Lee of Chong Kun Dang, President Eun-sun Kim of Boryung Pharm and CEO Kwan-soon Lee of Hanmi Pharm, will accompany Presiden...
Over-evaluated medical device companies with 4.5 PBR
It was known that the price-to-book ratio(PBR) of domestic medical device companies is estimated at 4.5 in average, becoming much higher than the ratio of the pharmaceutical industry.
According to the analysis result...
What will be main domestic pharmaceutical products of Amgen soon to be launched?
Domestic products of Amgen which will be officially launched have been visualized.
According to the industry concerned on the 12th, the Korean branch of Amgen turned in applications of ‘Kyprolis(carfilzomib),’ a mult...
‘Liver cancer and liver diseases’ cause over KRW 7 trillion economic damages
It was indicated the principal causes letting down parents in 40s and 50s, who are taking charge in the domestic economy, is ‘liver cancer and liver diseases.’
According to the national cause of death statistics in K...
Complete pharmaceutical distribution increased KRW 3 trillion last year
It was observed the size of complete pharmaceutical product distribution dealt in the domestic market exceeded KRW 48.9 trillion facing KRW 50 trillion soon.
The Korea Pharmaceutical Information Service Center(Center...
‘Is there a clear way to eradicate illegal rebates?’ said the pharmaceutical association and industry
Is there a strong and clear way to solve this?
The pharmaceutical association and the pharmaceutical industry have been concerned. It was observed excessive competition for generic products that are already or expect...
Janssen vs Otsuka expects domestic competition for long-acting schizophrenia drugss
In the schizophrenia treatment market, competition to introduce long-acting injections has become active.
Leading pharmaceutical companies in the field, Janssen and Otsuka, have released follow-up products in series....
Dabictrel approval has been withdrawn even without debut
Hanwha Chemical has voluntarily withdrawn the product approval of ‘Dabictrel(etanercept),’ a Enbrel biosimilar.
Thus, a domestic biosimilar which was approved to be commercialized for the third time has now been disa...
It is unlike Baraclude generics will covet the Viread market
Launched with their low-price advantage, generic products of ‘Baraclude(generic name: entecavir),’ a chronic hepatitis B treatment, seem hard to impact on the market owned by ‘Viread(generic name: tenofovir).’
This i...
